Article Text
Abstract
There is a bidirectional relationship between hepatitis C and type 2 diabetes. The risk for developing type 2 diabetes is increased in patients with chronic hepatitis C virus (HCV) infection—with the prevalence of diabetes ranging from 13% to 33%. This is likely underpinned by insulin resistance. Type 2 diabetes may also be a predisposing factor for HCV infection. The new non-interferon-based therapeutic regimens for hepatitis C have transformed care and can eradicate disease. In this report, we show how such a regimen eradicated viral load, improved hepatocellular blood markers and significantly improved dysglycaemia, such that all glucose-lowering medication could be stopped.
- Diabetes
- Infection (gastroenterology)
- Hepatitis C
- Hepatitis and other GI infections
Statistics from Altmetric.com
Footnotes
Twitter @surendranaarthi, @mbwhyte1
Contributors AS has written the case report. AB has contributed to the areas outlining the case presentation and the image. MBW is the senior author and was the primary consultant who looked after the patient. He also has critically reviewed the report and made changes.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.